BRAYDEN JOLLEY: Open Payments
NPI 1679231443 · BILOXI, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,855 in 70 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $1,855
Food & beverage: $1,855
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $406 |
| UCB, Inc. | 12 | $348 |
| GENZYME CORPORATION | 12 | $179 |
| Arcutis Biotherapeutics, Inc. | 3 | $164 |
| Galderma Laboratories, L.P. | 10 | $141 |
| ABBVIE INC. | 5 | $111 |
| Almirall LLC | 4 | $102 |
| Novartis Pharmaceuticals Corporation | 4 | $95 |
| Regeneron Healthcare Solutions, Inc. | 2 | $60 |
| Lilly USA, LLC | 2 | $53 |
Products named: TREMFYA, Bimzelx, DUPIXENT, Zoryve, NEMLUVIO, SKYRIZI, Klisyri, COSENTYX.
Industry payments across MS — which companies pay providers there.
